Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012.
about
The 2009 H1N1 Pandemic Influenza in KoreaThe Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in FinlandM2e-Based Universal Influenza A VaccinesProtection of young children from influenza through universal vaccination.Spatio-temporal patterns of proportions of influenza B casesReview of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.Characteristics of seasonal influenza A and B in Latin America: Influenza surveillance data from ten countries.Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled studyEpidemiology of influenza B/Yamagata and B/Victoria lineages in South Africa, 2005-2014.Molecular epidemiology and phylogenetic analyses of influenza B virus in Thailand during 2010 to 2014.Ten influenza seasons in France: distribution and timing of influenza A and B circulation, 2003-2013Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.Evolution of Influenza B Virus in Kuala Lumpur, Malaysia, between 1995 and 2008.Epidemiological and Virological Characterization of Influenza B Virus Infections.Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodiesInfluenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineageThe Molecular Epidemiology and Evolutionary Dynamics of Influenza B Virus in Two Italian Regions during 2010-2015: The Experience of Sicily and LiguriaInfluenza vaccination in high-risk groups: a revision of existing guidelines and rationale for an evidence-based preventive strategy.A comprehensive review of the epidemiology and disease burden of Influenza B in 9 European countries.Mismatching between circulating strains and vaccine strains of influenza: Effect on Hajj pilgrims from both hemispheresImmunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study.Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in EuropeEpidemiology of influenza B in Australia: 2001-2014 influenza seasons.The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors.Live attenuated influenza vaccine tetravalent: a clinical review.A systematic review of the health economic consequences of quadrivalent influenza vaccination.Childhood and adolescent influenza vaccination in Europe: A review of current policies and recommendations for the future.Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control.Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes.Trends of influenza B during the 2010-2016 seasons in 2 regions of north and south Italy: The impact of the vaccine mismatch on influenza immunisation strategy.A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.[Quadrivalent influenza vaccines].Editorial commentary: Changing epidemiology of influenza B virus.Evidence for Viral Interference and Cross-reactive Protective Immunity Between Influenza B Virus Lineages.Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity.A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses.Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults.Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses.Heterogeneous estimates of influenza virus types A and B in the elderly: Results of a meta-regression analysis.
P2860
Q26749483-6ADCFA11-B4E3-4A14-9972-A1F5118A6F7DQ26779541-E20D66B5-82D5-48C1-B870-F8812F120773Q26783493-8225553B-3981-4E0B-9E59-95A08A91C11DQ27693242-BCB6B81B-B69E-4D44-9EAD-C526E297C45FQ28365178-8B08D28F-4A8E-4AE0-BB68-C110BF5A326CQ30241087-79A7A02B-3B89-44D2-A6F3-244AAACCDD84Q30400386-E85F191E-4DF1-4ABB-A69E-EFF84C0EFB00Q33434855-21E3B2A2-12AF-4379-BFF0-D9A848B9D453Q33727940-AC5E318F-77ED-430A-8323-D9A87A61D501Q34989377-79114319-A440-4085-8727-1A75DE78E405Q35750762-C4C30715-8571-4850-9BD5-619170375906Q35887612-8F44847B-9941-42F4-A5CC-FC2A5ABAAA34Q35973695-84FB4DA6-5607-40E2-8F79-9A1F426FD20CQ36105903-E5643841-3D0E-46BE-828E-E60339CC1CBDQ36350940-E44E6617-3335-4CE0-9839-D33598C72FF2Q36376605-692B43CF-82D3-4A1D-95CD-6376241DF5F9Q36847186-496AA656-8230-4FA0-9821-143D7B287FF5Q37011561-CD4C8E1F-72E7-4DFB-B2F8-523C270CDF14Q37130821-44EE47D1-AFCB-4222-89F3-53FF348EC89EQ37135267-CBEC2C1E-E0E6-404E-A5B1-542859385B29Q37264968-E323099F-7122-4D9E-9868-E19C33381DAAQ37264984-6FD62564-5B0B-4DBA-B615-490AF8F3E2D6Q37638402-F94E1122-99DE-46FC-971B-F7666F9216F4Q38388047-29D32D84-1F92-4B82-BE5F-A6EA2701B22BQ38416489-CC8B5D3F-615E-451F-8FA3-6F44EC7CAC82Q38671179-E7093569-A661-45C8-B75E-3639DAAE6584Q38734736-A981BE1C-E4B9-4A4A-BBF1-5200F5DF4ECEQ38868293-82CAC6BD-FC8B-4918-86CD-589C89B56C97Q39322780-5CEB12E7-F73D-4C32-9AC9-72DE8B500F68Q40075978-9FA1B664-DCD4-43A6-B3BB-697766547A1FQ40122593-E24216DD-A19E-4144-B0D5-1906AE66853BQ40180049-BBD4EBE5-8A48-489F-8634-62A994290733Q41389931-0225F364-D0B4-433F-8A25-461252396771Q45345443-3595D816-8AAA-4748-AFE2-40718C038A05Q47555103-F53D58E7-B9BC-46F5-9651-9FF76E4AF48DQ47558906-EFDCBD18-1143-4426-A34E-4A5BBB92A7CAQ47608146-36AA9C1B-2137-41DB-B8FC-7B9D89C789DAQ50420352-8BAF11BC-0CFF-45C5-BDF2-54D974203FDBQ52673291-CCD21105-1C6C-444A-8191-DBCB8E5E220EQ54263414-EE7F1FB6-63DE-4A9E-9BD8-EACAA686B565
P2860
Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Impact of influenza B lineage- ...... irculating viruses, 1999-2012.
@ast
Impact of influenza B lineage- ...... irculating viruses, 1999-2012.
@en
type
label
Impact of influenza B lineage- ...... irculating viruses, 1999-2012.
@ast
Impact of influenza B lineage- ...... irculating viruses, 1999-2012.
@en
prefLabel
Impact of influenza B lineage- ...... irculating viruses, 1999-2012.
@ast
Impact of influenza B lineage- ...... irculating viruses, 1999-2012.
@en
P2860
P356
P1476
Impact of influenza B lineage- ...... irculating viruses, 1999-2012.
@en
P2093
Thedi Ziegler
P2860
P304
P356
10.1093/CID/CIU664
P407
P577
2014-08-19T00:00:00Z